Progress and prospect on treatment for radioiodine-refractory thyroid cancer

Most patients with differentiated thyroid cancer benefit from surgery, radioactive iodine-131 therapy and TSH suppression therapy, resulting in a favorable prognosis. However, once radioactive iodine refractory thyroid cancer (RAIR-DTC) develops, the prognosis becomes significantly poorer, treatment...

Full description

Bibliographic Details

Published in:	Zhongguo aizheng zazhi
Main Author:	GENG Qianqian, YANG Aimin
Format:	Article
Language:	English
Published:	Editorial Office of China Oncology 2025-01-01
Subjects:	|radioactive iodine refractory|differentiated thyroid cancer|targeted therapy|immunotherapy|radionuclide therapy|tyrosine kinase inhibitor
Online Access:	http://www.china-oncology.com/fileup/1007-3639/PDF/1739775845187-2003910516.pdf